Clinical Trials Logo

Mast Cell Activation Syndrome clinical trials

View clinical trials related to Mast Cell Activation Syndrome.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04978740 Completed - Clinical trials for Mast Cell Activation Syndrome

Ocular and Palpebral Manifestations of Mastocytosis (MOOMA)

Start date: July 30, 2021
Phase: N/A
Study type: Interventional

Mastocytosis is a rare condition characterized by an accumulation of mast cell cells in one or more organs such as the liver, bone marrow, spleen and intestines. Its prevalence in the general population is 1 in 10,000. This pathology is due to the proliferation of a mast cell clone and the excessive release of inflammatory mediators which lead to abnormal tissue infiltration. To date, there are only a few cases reporting ocular and orbital manifestations of mastocytosis. Our prospective, interventional and single-center study consist in describing the ocular functional manifestations and ocular surface abnormalities of patients with systemic and cutaneous mastocytosis.

NCT ID: NCT03406325 Completed - Asthma Clinical Trials

Mast Cell Activation Test in Allergic Disease

Start date: February 1, 2018
Phase:
Study type: Observational

Activation of mast cells in the immune system is known to cause allergic reactions sometimes with severe systemic symptoms. The investigators have recently developed a blood-based mast cell activation diagnostic test in which levels of functional activation in-vitro in primary cultured mast cells generated from the peripheral blood of single individuals can be assessed. It is the hypothesis that the test can be used to predict the potential state of in-vivo mast cell activation in any individual based on the functional activation profiles exhibited by their cultured mast cells. The investigators now wish to translate their in-vitro findings in a pilot study to disease groups where mast cell activation is expected to be high. These include highly allergic individuals; those with chronic idiopathic urticaria; those with mastocytosis; and those with the mast cell activation syndrome. Furthermore, they will use the functional genomics approach to identify gene expression biomarkers that are correlated with such diseases. The results will be compared with data that have been collected from a cohort of healthy control blood donors.